Warp Sciences 215 Million Funding 865 Million Valuation Explained: Ex-OpenAI Science Chief Builds a Robot Chemistry Lab in the US

Illustrative image: Unsplash (free Unsplash licence) — pipetting into a microplate, the kind of molecule-making bench work Warp Sciences plans to automate

TL;DR — The warp sciences 215 million funding 865 million valuation explained story in one line: Warp Sciences emerged from stealth on 22 October 2026 with $215 million led by Lightspeed to build a US robot-and-AI chemistry lab that makes and tests drug molecules for biotech and pharma teams.

📌 KEY HIGHLIGHTS

• The launch: Warp Sciences came out of stealth on 22 October 2026 with $215 million in funding to build a US-based chemistry contract research organisation (CRO) — expert chemists, AI and robotics under one roof, making and testing the molecules drug-discovery teams need.
• The valuation: $865 million post-money, according to the company as reported by Bloomberg and TechCrunch — a near-unicorn price on day one of public life, for a services business with no shipped public product yet.
• Who led and joined: Lightspeed led the round. Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures and more than a dozen other firms joined, alongside angels including Coinbase CEO Brian Armstrong, OpenAI CFO Sarah Friar and Figma CEO Dylan Field.
• The founders: Kevin Weil (ex-OpenAI chief product officer and VP of Science) as CEO, with Sol Reisberg (medicinal chemistry, Terremoto Biosciences), DJ Patil (the first US Chief Data Scientist) and Mano Paluri (Meta Superintelligence Labs VP, FAIR founding member).
• The bet: the slowest bench step in drug discovery — making hundreds or thousands of variants of a promising molecule and testing them — is still largely outsourced to contract labs in China. Warp wants to bring it back to the US and automate it, and says it will develop no drugs of its own.

What happened?

On 22 October 2026, Warp Sciences announced itself to the world with $215 million already raised. That is unusual in two ways. First, the size: stealth-stage startups normally emerge with a seed round and a promise, not with a quarter-billion-dollar war chest. Second, the business itself: Warp is not another AI model company. It is building physical laboratory infrastructure — a chemistry CRO in the United States where experienced chemists, AI models and robots together produce the research compounds that biotech and pharmaceutical teams need to find new medicines.

The founding logic, in CEO Kevin Weil's words in the announcement, is that AI has dramatically accelerated software engineering and mathematics but has yet to make the same impact in the physical sciences — because chemistry and biology only move forward when you make something, test it, and learn from the result. Warp's flywheel is exactly that loop: experimental data trains better AI, better AI powers more capable labs, and scientists get to test more ideas per unit of time. Weil knows the AI-for-science world from the inside — at OpenAI he was chief product officer before leading its science work — and his co-founders cover the rest of the stack: Reisberg brings drug-hunting chemistry, Patil brings data infrastructure and healthcare operations, and Paluri brings large-scale AI systems from Meta.

Warp Sciences 215 million funding 865 million valuation explained — the round and the team in a table

Item	What was announced	Why it matters
Funding	$215 million, emerged from stealth 22 Oct 2026	One of the largest stealth exits of 2026 — capital to build labs, not just software
Valuation	$865 million post-money (company-stated, via Bloomberg/TechCrunch)	Prices in the founders' track records and the size of the outsourcing market, before any public product
Lead investor	Lightspeed; Premji Invest, Mayfield, IVP, Lux, Menlo Ventures and 15+ others participated	Premji Invest gives the round an India link — it is the investment arm associated with Wipro founder Azim Premji
Founders	Kevin Weil (CEO, ex-OpenAI), Sol Reisberg (CSO, Terremoto), DJ Patil (COO, first US Chief Data Scientist), Mano Paluri (CTO, ex-Meta Superintelligence)	AI, chemistry, data and robotics leadership in one founding team; early hires add Genesis, Skild AI, 1X, Genentech and Lawrence Livermore experience
First service	Lead optimization analog synthesis — making molecule variations for customers to compare	Targets a specific, paid-for bottleneck instead of promising end-to-end drug discovery
What it is NOT	No proprietary drug pipeline; customers choose the molecules and keep control of their programs	Warp sells infrastructure to drug hunters rather than competing with them

To see how fast AI money is moving this month, compare this launch with our Flapping Airplanes 1 billion Series A 6 billion valuation explainer — another research lab priced on team and ambition — and our DeepSeek 15 billion funding valuation IPO explained post on the other side of the Pacific race.

Illustrative image: Unsplash (free Unsplash licence) — cells under fluorescence microscopy, representing the experimental results Warp's AI models will learn from

Why it matters for USA readers — and the China outsourcing question

Warp is explicitly a reshoring story. For years, the labour-intensive work of synthesising thousands of molecule variations has gone to contractors in China such as WuXi AppTec, which compete on speed and cost. The company's announcement cites a 2024 Biotechnology Innovation Organization survey in which 74% of respondents reported contracts with Chinese companies for preclinical and clinical services, and notes the BIOSECURE Act, signed into law in December 2025, which set up a framework for restrictions on federal procurement and funding involving designated biotechnology companies of concern. Reisberg's pitch to customers is blunt: the same calibre of chemistry services in the US, with intellectual-property protection at the centre, and without the price premium US boutique CROs currently charge.

The automation plan is what could make that economics work. Bloomberg's reporting describes a team of roughly 20 people that has already acquired robotic arms and AI chips, with chemists wearing cameras and pressure-sensing gloves so robots can learn physical lab tasks — the goal being labs that run and learn around the clock. Treat those operational details as early reporting, not proven capacity: no customer names, timelines or throughput figures have been published yet. The same week also saw OpenAI buy Orchestra Bio to bring AI agents into drug-development operations, a sign that the biggest AI labs see pharma workflows as the next battleground — Warp is the independent, physical-world version of that same thesis. For a different flavour of the AI funding race, see our Legora 550 million Series E 8.8 billion valuation legal AI explainer.

Should you care?

✅ Care if you work in biotech, pharma, or invest in AI infrastructure. A $215 million cheque for laboratory capacity — not models — says investors now believe the scarce asset in AI-for-science is real experimental data, and Warp's founders are unusually credible people to test that idea. ⏳ Everyone else: note it as a signal and watch the proof points — first named customers, published turnaround times versus overseas CROs, and whether the robot-trained lab actually gets cheaper per compound. The honest caveat: an $865 million valuation on launch day prices in years of flawless execution against entrenched, low-cost competitors, and none of that execution has been demonstrated publicly yet.

FAQs

How much did Warp Sciences raise, and what is its valuation?
Warp Sciences emerged from stealth on 22 October 2026 with $215 million in funding. The round values the company at $865 million post-money, according to the company as reported by Bloomberg and TechCrunch; the valuation figure does not appear in the company's own Business Wire announcement, so we attribute it rather than state it as audited fact.

Who founded Warp Sciences?
Four co-founders: Kevin Weil (CEO), most recently OpenAI's chief product officer and VP of Science; Sol Reisberg (chief scientific officer), who held medicinal chemistry leadership roles at Terremoto Biosciences; DJ Patil (COO), a founding executive at Devoted Health and the first US Chief Data Scientist at the White House; and Mano Paluri (CTO), a VP at Meta Superintelligence Labs and a founding member of FAIR.

What does Warp Sciences do?
Warp is building a US-based chemistry contract research organisation that makes and tests molecules for biotech and pharma research teams, combining expert chemists with AI and robotics. Its first service is lead optimization analog synthesis — producing variations of a promising molecule so scientists can compare them — and it has no drug pipeline of its own: customers decide what to pursue and keep control of their programs.

Who led Warp Sciences' $215 million funding round?
Lightspeed led the round. Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures and more than a dozen other firms participated, and the angel list includes Brian Armstrong (Coinbase), Sarah Friar and Mark Chen (OpenAI), Dylan Field (Figma), Ion Stoica (Databricks) and Fidji Simo.

TAKEAWAY
The AI race just bought a chemistry lab: $215 million says the next advantage in drug discovery is not a bigger model but robots generating real experimental data on US soil.
Follow USA Tech on TechByCountry for the next hourly update.

Sources: Warp Sciences — company announcement via Business Wire, syndicated in full (22 Oct 2026) • TechCrunch — Former OpenAI science lead launches Warp Science to automate wet labs with robots (22 Oct 2026) • Bloomberg — Ex-OpenAI Science Head Launches Startup With $215 Million (22 Oct 2026) • CryptoBriefing — Ex-OpenAI executive raises $215 million for AI drug development startup (22 Oct 2026). Checked 23 Oct 2026.